EDISON EQUITY RESEARCH - AMARANTUS BIOSCIENCE
20 August 2014 - 3:28AM
InvestorsHub NewsWire
Edison Investment Research: Amarantus BioScience
- Potential of LymPro indicated
Amarantus presented data of its blood-based
diagnostic test for Alzheimer’s disease (AD), LymPro, at the
Alzheimer’s Association International Conference (AAIC). Data from
a 41-patient trial with an optimised test showed a specificity of
81% and a sensitivity of 73%. Commercial launch of LymPro as a
laboratory-developed test remains on track for H214. MANF has also
started formal preclinical testing and could begin clinical
development in 2015. Eltoprazine is expected to start a Phase IIb
trial in the coming months.
Amarantus BioScience is a US-based biotechnology
company developing diagnostic and therapeutic products. Its lead
product is LymPro, a blood-based diagnostic test for Alzheimer’s
disease. It also has two therapeutic products in development,
eltoprazine in Phase II and MANF in preclinical
studies.
To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/amarantus-bioscience1
Click
here to view all of Edison
Investment Research's published reports.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Amarantus Bioscience Holdings Inc (CE) (OTCMarkets): 0 recent articles
More Amarantus Bioscience Holdings, Inc. (QB) News Articles